Nothing Special   »   [go: up one dir, main page]

ATE325623T1 - Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en) - Google Patents

Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)

Info

Publication number
ATE325623T1
ATE325623T1 AT00961900T AT00961900T ATE325623T1 AT E325623 T1 ATE325623 T1 AT E325623T1 AT 00961900 T AT00961900 T AT 00961900T AT 00961900 T AT00961900 T AT 00961900T AT E325623 T1 ATE325623 T1 AT E325623T1
Authority
AT
Austria
Prior art keywords
chronic renal
therapies
renal insufficiency
integrin antagonist
risk
Prior art date
Application number
AT00961900T
Other languages
English (en)
Inventor
Andrew Allen
Charles Pusey
Roy Lobb
Original Assignee
Biogen Idec Inc
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Imperial College filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE325623T1 publication Critical patent/ATE325623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00961900T 1999-09-14 2000-09-14 Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en) ATE325623T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15382699P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ATE325623T1 true ATE325623T1 (de) 2006-06-15

Family

ID=22548902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961900T ATE325623T1 (de) 1999-09-14 2000-09-14 Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)

Country Status (13)

Country Link
US (3) US20030007969A1 (de)
EP (1) EP1214091B1 (de)
JP (3) JP4975922B2 (de)
AT (1) ATE325623T1 (de)
AU (1) AU783266B2 (de)
CA (1) CA2384948C (de)
CY (1) CY1105117T1 (de)
DE (1) DE60027907T2 (de)
DK (1) DK1214091T3 (de)
ES (1) ES2263485T3 (de)
NZ (1) NZ517781A (de)
PT (1) PT1214091E (de)
WO (1) WO2001019396A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
JP4684991B2 (ja) 2003-01-31 2011-05-18 ボストン サイエンティフィック リミテッド 薬物添加ナノカプセルを用いる局所的薬物デリバリー
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5843438A (en) * 1992-11-13 1998-12-01 Board Of Regents University Of Washington Peripheralization of hematopoietic stem cells
JPH08507680A (ja) * 1993-01-12 1996-08-20 バイオジェン インコーポレイテッド 組換え抗ｖｌａ４抗体分子
DK0682529T4 (da) * 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
IL128221A (en) * 1996-07-25 2003-12-10 Biogen Inc Cell adhesion inhibitors
EA004145B1 (ru) * 1998-05-22 2004-02-26 Бойз Таун Нэшнл Рисёрч Хоспитал ПРИМЕНЕНИЕ ИНГИБИТОРОВ РЕЦЕПТОРОВ-ИНТЕГРИНОВ α1β1 И ИНГИБИТОРОВ ТРФ-β1 ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЯ ПОЧЕК
DE69940206D1 (de) * 1998-09-14 2009-02-12 Univ Texas Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods
EP2332578A1 (de) * 1999-12-16 2011-06-15 Biogen Idec MA Inc. Verfahren zur Behandlung von ischämischen oder hämorrhagischen Traumata des Zentralnervensystems unter Verwendung von Alpha4-Integrin-Antagonisten

Also Published As

Publication number Publication date
DE60027907D1 (de) 2006-06-14
WO2001019396A1 (en) 2001-03-22
US20110305686A1 (en) 2011-12-15
EP1214091B1 (de) 2006-05-10
JP2003509380A (ja) 2003-03-11
AU7379200A (en) 2001-04-17
NZ517781A (en) 2004-01-30
ES2263485T3 (es) 2006-12-16
US20030007969A1 (en) 2003-01-09
PT1214091E (pt) 2006-09-29
CY1105117T1 (el) 2010-03-03
CA2384948C (en) 2013-07-16
DE60027907T2 (de) 2007-01-04
US20140234299A1 (en) 2014-08-21
CA2384948A1 (en) 2001-03-22
AU783266B2 (en) 2005-10-06
EP1214091A1 (de) 2002-06-19
JP5463316B2 (ja) 2014-04-09
JP4975922B2 (ja) 2012-07-11
DK1214091T3 (da) 2006-08-28
JP2011116791A (ja) 2011-06-16
JP2013116916A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
ATE507210T1 (de) Chinazolinon modulatoren von nukleinrezeptoren
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
ATE245997T1 (de) Therapien des chronischen nierenversagens
DE60322527D1 (de) Rapiesystem
WO2005112980A3 (en) Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy
ATE325623T1 (de) Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
Teplan et al. Effects of low-protein diet supplemented with ketoacids and erythropoietin in chronic renal failure: a long-term metabolic study.
Berntorp If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia
Warpeha Resurfacing the burned face.
UA86749C2 (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
Hlubocka et al. Is mild essential hypertension without obvious organ complications and risk factors associated with increased levels of circulating markers of endothelial dysfunction? Effect of ACE inhibitor therapy
TR200003502T2 (tr) Bir Piperidin Maddesi P Antagonistini İçeren Mikroemülsiyon Prekonsantratları
Pasha et al. Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures.
Saito et al. Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon.
DE60313444D1 (de) Vegf-peptide und deren verwendung
ATE274920T1 (de) Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen
Mahon et al. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Chahine et al. Taurine and myocardial noradrenaline.
Opsahl et al. Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone.
Morganti et al. Acute and chronic converting enzyme inhibition reduces the vasomotor response to reflex sympathetic activation in man.
Dainer Octreotide acetate therapy for hypercalcemia complicating small cell carcinoma of the lung.
WO2003103478A3 (en) METHODS OF USING ADAMTS-12, AN INTEGRIN AND METALLOPROTEASE WITH THROMBOSPONDIN PATTERNS
Shrivastava et al. Ensuring sound mental health in the workplace
Materson Angiotensin converting enzyme inhibitors in the treatment of hypertension.
AU2003293742A1 (en) Methods for measuring the activity of g(alpha)i-coupled or g(alpha)o-coupled receptors by means of the ca2+ influx in cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1214091

Country of ref document: EP